Barclays lowered the firm's price target on Amdocs to $92 from $111 and keeps an Overweight rating on the shares. The views the company's results "resilient", with several wins in strategic domains. With the macro backdrop weighing on Amdocs' end markets, investors will focus on the company's double-digit earnings return policy, the analyst tells investors in a research note.
